Turk Ilac ve Serum Sanayi AS
Turk Ilac Ve Serum Sanayi Anonim Sirketi produces and sells human tablets, parenteral solutions, nutritional solutions, amino acids, and other chemicals in Turkey. It also offers bulb, biological, and serum products, as well as medical devices. The company was founded in 2010 and is headquartered in Ankara, Turkey.
Turk Ilac ve Serum Sanayi AS (TRILC) - Net Assets
Latest net assets as of September 2025: TL1.91 Billion TRY
Based on the latest financial reports, Turk Ilac ve Serum Sanayi AS (TRILC) has net assets worth TL1.91 Billion TRY as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (TL6.12 Billion) and total liabilities (TL4.21 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | TL1.91 Billion |
| % of Total Assets | 31.21% |
| Annual Growth Rate | 77.02% |
| 5-Year Change | 1198.85% |
| 10-Year Change | N/A |
| Growth Volatility | 72.87 |
Turk Ilac ve Serum Sanayi AS - Net Assets Trend (2018–2024)
This chart illustrates how Turk Ilac ve Serum Sanayi AS's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Turk Ilac ve Serum Sanayi AS (2018–2024)
The table below shows the annual net assets of Turk Ilac ve Serum Sanayi AS from 2018 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | TL1.92 Billion | +8.39% |
| 2023-12-31 | TL1.78 Billion | +214.34% |
| 2022-12-31 | TL564.69 Million | +74.25% |
| 2021-12-31 | TL324.08 Million | +118.78% |
| 2020-12-31 | TL148.13 Million | +126.92% |
| 2019-12-31 | TL65.28 Million | +4.49% |
| 2018-12-31 | TL62.47 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Turk Ilac ve Serum Sanayi AS's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 1622.1% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | TL621.05 Million | 32.28% |
| Other Components | TL1.30 Billion | 67.72% |
| Total Equity | TL1.92 Billion | 100.00% |
Turk Ilac ve Serum Sanayi AS Competitors by Market Cap
The table below lists competitors of Turk Ilac ve Serum Sanayi AS ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Actinium Pharmaceuticals Inc
NYSE MKT:ATNM
|
$34.63 Million |
|
Mermaid Maritime Public Company Limited
PINK:MMMPF
|
$34.63 Million |
|
Gulshan Polyols Limited
NSE:GULPOLY
|
$34.64 Million |
|
Advice It Infinite Pcl
BK:ADVICE
|
$34.64 Million |
|
Madison County Financial Inc
PINK:MCBK
|
$34.61 Million |
|
Connect Biopharma Holdings Ltd
NASDAQ:CNTB
|
$34.61 Million |
|
Harmony Electronics
TWO:8182
|
$34.59 Million |
|
Tamul Multimedia Co. Ltd
KQ:093640
|
$34.58 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Turk Ilac ve Serum Sanayi AS's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 1,775,064,192 to 1,923,985,348, a change of 148,921,156 (8.4%).
- Net income of 72,358,822 contributed positively to equity growth.
- Other factors increased equity by 76,562,334.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | TL72.36 Million | +3.76% |
| Other Changes | TL76.56 Million | +3.98% |
| Total Change | TL- | 8.39% |
Book Value vs Market Value Analysis
This analysis compares Turk Ilac ve Serum Sanayi AS's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.33x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 41.08x to 1.33x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2018-12-31 | TL0.39 | TL15.86 | x |
| 2019-12-31 | TL0.40 | TL15.86 | x |
| 2020-12-31 | TL0.92 | TL15.86 | x |
| 2021-12-31 | TL2.00 | TL15.86 | x |
| 2022-12-31 | TL3.49 | TL15.86 | x |
| 2023-12-31 | TL10.97 | TL15.86 | x |
| 2024-12-31 | TL11.89 | TL15.86 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Turk Ilac ve Serum Sanayi AS utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 3.76%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.82%
- • Asset Turnover: 0.64x
- • Equity Multiplier: 2.08x
- Recent ROE (3.76%) is below the historical average (14.54%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2018 | 23.04% | 14.79% | 0.51x | 3.04x | TL8.15 Million |
| 2019 | 20.65% | 8.86% | 0.57x | 4.09x | TL6.95 Million |
| 2020 | 22.50% | 16.71% | 0.50x | 2.69x | TL18.52 Million |
| 2021 | 11.46% | 5.52% | 1.09x | 1.91x | TL4.73 Million |
| 2022 | 11.75% | 7.96% | 0.80x | 1.85x | TL9.91 Million |
| 2023 | 8.60% | 5.50% | 0.98x | 1.59x | TL-24.87 Million |
| 2024 | 3.76% | 2.82% | 0.64x | 2.08x | TL-120.04 Million |
Industry Comparison
This section compares Turk Ilac ve Serum Sanayi AS's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $19,436,956,043,489
- Average return on equity (ROE) among peers: 11.11%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Turk Ilac ve Serum Sanayi AS (TRILC) | TL1.91 Billion | 23.04% | 2.20x | $34.61 Million |
| Deva Holding AS (DEVA) | $411.91 Million | 2.12% | 1.17x | $62.43 Million |
| EIS Eczacibasi Ilac Sinai ve Finansal Yatirimlar Sanayi ve Ticaret AS (ECILC) | $58.31 Trillion | 7.00% | 1.17x | $428.67 Million |
| Gen Ilac ve Saglik Urunleri Sanayi ve Ticaret AS (GENIL) | $1.28 Billion | 24.20% | 0.65x | $69.33 Million |